# Agent ‡∏ï‡∏±‡∏ß‡∏ó‡∏µ‡πà 2: Fundamental Analysis (‡∏ó‡∏∏‡∏Å Task ‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ‡∏ï‡∏±‡∏ß‡πÄ‡∏•‡∏Ç‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á)

---

## 1. ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏Ç‡πá‡∏á‡πÅ‡∏Å‡∏£‡πà‡∏á‡∏ó‡∏≤‡∏á‡∏Å‡∏≤‡∏£‡πÄ‡∏á‡∏¥‡∏ô (Financial Strength)

‡∏ß‡∏±‡∏î‡∏Ñ‡∏ß‡∏≤‡∏°‡∏°‡∏±‡πà‡∏ô‡∏Ñ‡∏á‡∏Ç‡∏≠‡∏á‡∏ö‡∏£‡∏¥‡∏©‡∏±‡∏ó‡πÉ‡∏ô‡πÅ‡∏á‡πà‡∏´‡∏ô‡∏µ‡πâ‡∏™‡∏¥‡∏ô ‡∏™‡∏†‡∏≤‡∏û‡∏Ñ‡∏•‡πà‡∏≠‡∏á ‡πÅ‡∏•‡∏∞‡∏Å‡∏£‡∏∞‡πÅ‡∏™‡πÄ‡∏á‡∏¥‡∏ô‡∏™‡∏î

- **Debt-to-Equity (D/E)**  
  - ‡∏Ñ‡πà‡∏≤‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≥‡∏ñ‡∏∑‡∏≠‡∏ß‡πà‡∏≤‡∏õ‡∏•‡∏≠‡∏î‡∏†‡∏±‡∏¢  
  - ‡∏´‡∏≤‡∏Å **ROE ‡∏™‡∏π‡∏á‡πÅ‡∏ï‡πà D/E ‡∏Å‡πá‡∏™‡∏π‡∏á** ‚Üí ‡∏ö‡∏£‡∏¥‡∏©‡∏±‡∏ó‡πÉ‡∏ä‡πâ‡∏´‡∏ô‡∏µ‡πâ‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Å‡∏≥‡πÑ‡∏£ = ‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á  
  - ‡∏Å‡∏•‡∏∏‡πà‡∏° Tech/SaaS ‡∏Ñ‡∏ß‡∏£‡∏°‡∏µ D/E ‡∏ï‡πà‡∏≥‡∏Å‡∏ß‡πà‡∏≤ 1

- **Current Ratio / Quick Ratio**  
  - ‡∏ß‡∏±‡∏î‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏ä‡∏≥‡∏£‡∏∞‡∏´‡∏ô‡∏µ‡πâ‡∏£‡∏∞‡∏¢‡∏∞‡∏™‡∏±‡πâ‡∏ô  
  - ‡∏Ñ‡πà‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏´‡∏°‡∏≤‡∏∞‡∏™‡∏° > **1.2**  
    - Retail ‡∏Ñ‡∏ß‡∏£‡∏™‡∏π‡∏á (‡∏°‡∏µ stock ‡πÄ‡∏¢‡∏≠‡∏∞)  
    - SaaS ‡∏ï‡πà‡∏≥‡πÑ‡∏î‡πâ (‡πÑ‡∏°‡πà‡∏°‡∏µ inventory)

- **Free Cash Flow (FCF)**  
  - ‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏Å‡∏ß‡πà‡∏≤‡∏Å‡∏≥‡πÑ‡∏£‡∏ó‡∏≤‡∏á‡∏ö‡∏±‡∏ç‡∏ä‡∏µ (EPS)  
  - EPS ‡πÇ‡∏ï‡πÅ‡∏ï‡πà FCF ‡πÑ‡∏°‡πà‡πÇ‡∏ï ‚Üí ‡∏Å‡∏≥‡πÑ‡∏£‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏ï‡πà‡∏≥  
  - SaaS ‡∏Ñ‡∏ß‡∏£‡∏°‡∏µ FCF ‡∏™‡∏π‡∏á / Biotech ‡∏´‡∏£‡∏∑‡∏≠ Startup ‡∏≠‡∏≤‡∏à‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏°‡∏µ

- **FCF Margin = FCF / Revenue**  
  - ‡∏ß‡∏±‡∏î‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏Ç‡∏≠‡∏á‡∏Å‡∏≥‡πÑ‡∏£‡πÉ‡∏ô‡πÄ‡∏ä‡∏¥‡∏á‡∏Å‡∏£‡∏∞‡πÅ‡∏™‡πÄ‡∏á‡∏¥‡∏ô‡∏™‡∏î  
    - SaaS ‡∏Ñ‡∏ß‡∏£ > 20‚Äì30%  
    - Manufacturing ‡∏≠‡∏≤‡∏à‡∏ï‡πà‡∏≥‡∏Å‡∏ß‡πà‡∏≤ 10%

**‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏ó‡∏µ‡πà‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ:**
- ‡∏á‡∏ö‡πÅ‡∏™‡∏î‡∏á‡∏ê‡∏≤‡∏ô‡∏∞‡∏Å‡∏≤‡∏£‡πÄ‡∏á‡∏¥‡∏ô (Balance Sheet)
- ‡∏á‡∏ö‡∏Å‡∏£‡∏∞‡πÅ‡∏™‡πÄ‡∏á‡∏¥‡∏ô‡∏™‡∏î (Cash Flow Statement)
- ‡∏£‡∏≤‡∏¢‡∏á‡∏≤‡∏ô‡∏õ‡∏£‡∏∞‡∏à‡∏≥‡∏õ‡∏µ (10-K, 56-1)
- ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏≠‡∏∏‡∏ï‡∏™‡∏≤‡∏´‡∏Å‡∏£‡∏£‡∏°‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÄ‡∏õ‡∏£‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏Ñ‡πà‡∏≤‡πÄ‡∏â‡∏•‡∏µ‡πà‡∏¢

---
<!-- 
## üîç ‡∏™‡∏£‡∏∏‡∏õ‡∏°‡∏∏‡∏°‡∏°‡∏≠‡∏á‡∏ó‡∏µ‡πà‡∏Ñ‡∏ß‡∏£‡πÑ‡∏î‡πâ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ß‡∏¥‡πÄ‡∏Ñ‡∏£‡∏≤‡∏∞‡∏´‡πå‡∏ô‡∏µ‡πâ

- ‡∏ö‡∏£‡∏¥‡∏©‡∏±‡∏ó‡∏°‡∏µ‡∏ê‡∏≤‡∏ô‡∏∞‡∏Å‡∏≤‡∏£‡πÄ‡∏á‡∏¥‡∏ô‡∏°‡∏±‡πà‡∏ô‡∏Ñ‡∏á‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà?
- ‡∏°‡∏µ‡∏´‡∏ô‡∏µ‡πâ‡∏™‡∏¥‡∏ô‡πÉ‡∏ô‡∏£‡∏∞‡∏î‡∏±‡∏ö‡∏ó‡∏µ‡πà‡∏õ‡∏•‡∏≠‡∏î‡∏†‡∏±‡∏¢‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÄ‡∏Å‡∏¥‡∏ô‡πÑ‡∏õ (D/E)?
- ‡∏°‡∏µ‡∏™‡∏†‡∏≤‡∏û‡∏Ñ‡∏•‡πà‡∏≠‡∏á‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠‡∏ï‡πà‡∏≠‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡∏ò‡∏∏‡∏£‡∏Å‡∏¥‡∏à‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà? (Current / Quick Ratio > 1.2)
- ‡∏Å‡∏£‡∏∞‡πÅ‡∏™‡πÄ‡∏á‡∏¥‡∏ô‡∏™‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡∏á‡∏≤‡∏ô‡πÄ‡∏õ‡πá‡∏ô‡∏ö‡∏ß‡∏Å‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà?
- ‡∏ö‡∏£‡∏¥‡∏©‡∏±‡∏ó‡∏°‡∏µ Free Cash Flow ‡∏à‡∏£‡∏¥‡∏á ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡πÅ‡∏Ñ‡πà‡∏Å‡∏≥‡πÑ‡∏£‡∏ó‡∏≤‡∏á‡∏ö‡∏±‡∏ç‡∏ä‡∏µ?
- ‡∏ö‡∏£‡∏¥‡∏©‡∏±‡∏ó‡πÅ‡∏õ‡∏•‡∏á‡∏£‡∏≤‡∏¢‡πÑ‡∏î‡πâ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≥‡πÑ‡∏£‡πÑ‡∏î‡πâ‡∏î‡∏µ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà?
- ‡∏ï‡πâ‡∏ô‡∏ó‡∏∏‡∏ô‡πÅ‡∏•‡∏∞‡∏Ñ‡πà‡∏≤‡πÉ‡∏ä‡πâ‡∏à‡πà‡∏≤‡∏¢‡∏≠‡∏¢‡∏π‡πà‡∏†‡∏≤‡∏¢‡πÉ‡∏ï‡πâ‡∏Å‡∏≤‡∏£‡∏Ñ‡∏ß‡∏ö‡∏Ñ‡∏∏‡∏°‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà?
- ‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≥‡πÑ‡∏£‡∏Ç‡∏±‡πâ‡∏ô‡∏ï‡πâ‡∏ô (GM), ‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡∏á‡∏≤‡∏ô (OM), ‡∏™‡∏∏‡∏ó‡∏ò‡∏¥ (NPM) ‡∏≠‡∏¢‡∏π‡πà‡πÉ‡∏ô‡∏£‡∏∞‡∏î‡∏±‡∏ö‡∏™‡∏π‡∏á‡πÄ‡∏°‡∏∑‡πà‡∏≠‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏Å‡∏±‡∏ö‡∏Å‡∏•‡∏∏‡πà‡∏°?
- ROE / ROA / ROIC ‡∏≠‡∏¢‡∏π‡πà‡πÉ‡∏ô‡∏£‡∏∞‡∏î‡∏±‡∏ö‡∏ó‡∏µ‡πà‡∏î‡∏µ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà?
- ROIC > WACC ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà (‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏û‡∏¥‡∏™‡∏π‡∏à‡∏ô‡πå‡∏ß‡πà‡∏≤‡∏ö‡∏£‡∏¥‡∏©‡∏±‡∏ó‡∏™‡∏£‡πâ‡∏≤‡∏á ‚Äú‡∏°‡∏π‡∏•‡∏Ñ‡πà‡∏≤‡πÄ‡∏û‡∏¥‡πà‡∏°‚Äù)?
- ‡∏£‡∏≤‡∏¢‡πÑ‡∏î‡πâ (Revenue) ‡πÄ‡∏ï‡∏¥‡∏ö‡πÇ‡∏ï‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà?
- EPS ‡πÇ‡∏ï‡∏à‡∏£‡∏¥‡∏á‡∏´‡∏£‡∏∑‡∏≠‡πÇ‡∏ï‡∏à‡∏≤‡∏Å‡∏£‡∏≤‡∏¢‡∏Å‡∏≤‡∏£‡∏û‡∏¥‡πÄ‡∏®‡∏©?
- FCF ‡πÄ‡∏ï‡∏¥‡∏ö‡πÇ‡∏ï‡∏Ñ‡∏ß‡∏ö‡∏Ñ‡∏π‡πà‡∏Å‡∏±‡∏ö EPS ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà?
- ‡∏ö‡∏£‡∏¥‡∏©‡∏±‡∏ó‡∏•‡∏á‡∏ó‡∏∏‡∏ô‡πÉ‡∏ô‡∏≠‡∏ô‡∏≤‡∏Ñ‡∏ï‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÄ‡∏´‡∏°‡∏≤‡∏∞‡∏™‡∏°‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà? (‡πÄ‡∏ä‡πà‡∏ô R&D, CapEx) -->
